Xu Kai-Feng, Wang Lan, Tian Xin-Lun, Gui Yao-Song, Peng Min, Cai Bai-Qiang, Zhu Yuan-Jue
Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Chin Med Sci J. 2010 Sep;25(3):140-5. doi: 10.1016/s1001-9294(10)60038-7.
To examine the correlation between the health-related quality of life measured by the St. George's Respiratory Questionnaire (SGRQ) and the commonly used physiological measures in lymphangioleiomyomatosis (LAM).
This study retrospectively analyzed the SGRQ scores and other measures (the Borg scale of breathlessness at rest, 6-minute walking distance, blood oxygen levels, and pulmonary function) of patients diagnosed and confirmed with LAM. Altogether 38 patients between June 2007 and November 2009 were included.
The mean values of the SGRQ three components (symptoms, activity, and impacts) and total scores in the LAM patients were 46.95 +/- 28.90, 58.47 +/- 25.41, 47.89 +/- 29.66, and 51.11 +/- 26.35, respectively. The SGRQ total or component scores were correlated well with the Borg scale of breathlessness, 6-minute walking distance, partial pressure of oxygen in arterial blood, spirometry and diffusion capacity of lung. There were poor correlations between SGRQ score and residual volume or total lung capacity. In our preliminary observation, sirolimus improved the SGRQ total and three component scores and the Borg scale of breathlessness significantly after 101-200 days of treatment (n = 6).
The SGRQ score in LAM is correlated well with physiological measures (Borg scale of breathlessness, 6-minute walking distance, blood oxygen levels, and pulmonary function tests). The SGRQ could therefore be recommended in baseline and follow-up evaluation of patients with LAM. Treatment with sirolimus, an inhibitor of mammalian target of rapamycin, may improve the quality of life and patient's perception of breathlessness in LAM.
探讨采用圣乔治呼吸问卷(SGRQ)测量的健康相关生活质量与淋巴管平滑肌瘤病(LAM)中常用生理指标之间的相关性。
本研究回顾性分析了经诊断和确诊为LAM患者的SGRQ评分及其他指标(静息时呼吸困难的Borg量表、6分钟步行距离、血氧水平和肺功能)。共纳入了2007年6月至2009年11月期间的38例患者。
LAM患者中SGRQ三个组成部分(症状、活动和影响)的平均值及总分分别为46.95±28.90、58.47±25.41、47.89±29.66和51.11±26.35。SGRQ总分或各组成部分得分与呼吸困难的Borg量表、6分钟步行距离、动脉血氧分压、肺量计和肺弥散能力均有良好的相关性。SGRQ评分与残气量或肺总量之间的相关性较差。在我们的初步观察中,西罗莫司治疗101 - 200天后,显著改善了SGRQ总分及三个组成部分得分以及呼吸困难的Borg量表评分(n = 6)。
LAM患者的SGRQ评分与生理指标(呼吸困难的Borg量表、6分钟步行距离、血氧水平和肺功能测试)有良好的相关性。因此,SGRQ可推荐用于LAM患者的基线和随访评估。雷帕霉素靶蛋白抑制剂西罗莫司治疗可能改善LAM患者的生活质量和患者对呼吸困难的感受。